References
Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624
Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7
El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69
Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506
Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the patient included in the study.
Additional information
Managed by Massimo Federici.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cosentino, C., Contento, M., Paganini, M. et al. Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment. Acta Diabetol 56, 1231–1233 (2019). https://doi.org/10.1007/s00592-019-01302-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01302-z